Suivre
Elodie Vauleon
Elodie Vauleon
Affiliation inconnue
Adresse e-mail validée de rennes.unicancer.fr
Titre
Citée par
Citée par
Année
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
J Edeline, E Boucher, Y Rolland, E Vauléon, M Pracht, C Perrin, ...
Cancer 118 (1), 147-156, 2012
3552012
DNA methylation in glioblastoma: impact on gene expression and clinical outcome
A Etcheverry, M Aubry, M De Tayrac, E Vauleon, R Boniface, F Guenot, ...
BMC genomics 11 (1), 1-11, 2010
2702010
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
T Avril, E Vauleon, E Chevet
Oncogenesis 6 (8), e373-e373, 2017
2212017
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial
A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, ...
Neuro-oncology, 2022
1842022
Dual IRE 1 RN ase functions dictate glioblastoma development
S Lhomond, T Avril, N Dejeans, K Voutetakis, D Doultsinos, M McMahon, ...
EMBO molecular medicine 10 (3), e7929, 2018
1522018
Overview of cellular immunotherapy for patients with glioblastoma
E Vauleon, T Avril, B Collet, J Mosser, V Quillien
Clinical and Developmental Immunology 2010, 2010
1372010
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ...
The Lancet 393 (10191), 2591-2598, 2019
1302019
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell …
J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ...
The Lancet Oncology 22 (4), 463-475, 2021
1222021
Human glioblastoma stem‐like cells are more sensitive to allogeneic NK and T cell‐mediated killing compared with serum‐cultured glioblastoma cells
T Avril, E Vauleon, A Hamlat, S Saikali, A Etcheverry, C Delmas, S Diabira, ...
Brain pathology 22 (2), 159-174, 2012
1152012
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an …
K Fizazi, A Maillard, N Penel, G Baciarello, D Allouache, G Daugaard, ...
Annals of Oncology 30, v851, 2019
972019
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions
T Avril, S Saikali, E Vauleon, A Jary, A Hamlat, M De Tayrac, J Mosser, ...
Journal of neuroimmunology 225 (1-2), 22-33, 2010
882010
Survival and prognostic factors in a series of adults with medulloblastomas
L Riffaud, S Saikali, E Leray, A Hamlat, C Haegelen, E Vauleon, ...
Journal of neurosurgery 111 (3), 478-487, 2009
852009
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
P Bady, S Kurscheid, M Delorenzi, T Gorlia, MJ van den Bent, ...
Acta neuropathologica 135 (4), 601-615, 2018
772018
LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 …
J Bourhis, C Sire, Y Tao, L Martin, M Alfonsi, JB Prevost, M Rives, ...
Annals of Oncology 31, S1168, 2020
692020
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the …
L Lebellec, B Chauffert, JY Blay, A Le Cesne, C Chevreau, E Bompas, ...
European Journal of Cancer 79, 119-128, 2017
682017
Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression
G Reyes-Botero, C Dehais, A Idbaih, N Martin-Duverneuil, M Lahutte, ...
Neuro-oncology 16 (5), 662-670, 2014
682014
CD90 expression controls migration and predicts dasatinib response in glioblastoma
T Avril, A Etcheverry, R Pineau, J Obacz, G Jegou, F Jouan, PJ Le Reste, ...
Clinical Cancer Research 23 (23), 7360-7374, 2017
632017
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN …
XS Sun, C Sire, Y Tao, L Martin, M Alfonsi, JB Prevost, M Rives, C Lafond, ...
Journal of Clinical Oncology 36 (15_suppl), 6018-6018, 2018
622018
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study
J Edeline, JL Raoul, E Vauleon, A Guillygomac’h, K Boudjema, E Boucher
World journal of gastroenterology: WJG 15 (6), 713, 2009
622009
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
D Figarella-Branger, POLA Network, K Mokhtari, POLA Network, ...
Neuro-oncology 16 (9), 1244-1254, 2014
572014
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20